NTLA
Intellia Therapeutics is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia\'s combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products.
Intellia Therapeutics, Inc. (NTLA) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Profitability (C-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C+ (2.8) | C+ (2.7) | C- (1.9) | C+ (2.7) | C+ (2.6) | C+ (2.6) |
| 2026-11-06 | B- (2.9) | C+ (2.7) | C- (1.9) | C+ (2.6) | C+ (2.7) | C+ (2.6) |
| 2026-10-30 | C+ (2.8) | C+ (2.6) | C- (1.9) | B- (2.9) | A+ (5.0) | B- (3.1) |
| 2026-10-23 | B- (2.9) | C+ (2.6) | C- (1.9) | C (2.3) | A+ (5.0) | B- (2.9) |
| 2026-10-16 | B- (2.9) | C+ (2.6) | C- (1.9) | C (2.3) | A+ (5.0) | B- (2.9) |